The Potential Role of Lipopeptide Biosurfactant Generated by Acinetobacter junii B6 on Leishmania Tropica: The Synergy of Lipopeptide Biosurfactant and Glucantime

Abstract

An in vitro investigation was carried out to assess how the lipopeptide biosurfactant (LPB) produced by Acinetobacter junii B6 affects Leishmania tropica infection and the associated cytokine gene expression in macrophages infected with L. tropica. Glucantime® (meglumine antimoniate, MA) and LPB were investigated for their leishmanicidal effect, alone and in combination (LPB + MA), using a colorimetric test and a macrophage model. Immunomodulatory impact was also evaluated through analysis of Th1 and Th2 cytokine gene expression in infected macrophages after treatment with MA and LPB, individually and in combination. The MA/LPB combination showed higher inhibitory impacts on L. tropica amastigotes and promastigotes than each alone. Cytokine gene expression confirmed LPB’s affinity to IFN-γ, affirming the elevated IL-12p40 and IFN- γ concentrations in addition to a reduction in the secretion of IL-10 in a dose-dependent manner, particularly in combined treatment. The results indicated higher effectiveness of LPB along with MA in the reduction of the parasite growth and promoting the immune reaction level, which may be considered as a possible therapeutic strategy to treat those with anthroponotic cutaneous leishmaniasis.